Find out the key headlines from the ESMO 2018 Congress (19–23 October, Munich, Germany).
A personalized prediction scheme for certain chronic blood cancers has been developed, based on new disease classifications.
Among prostate cancer patients, those with DNA mismatch repair mutations have particularly aggressive progression and reduced survivability. Though these tumors are more resistant to traditional treatment methods, a recent study has shown that they may be more susceptible to immunotherapy.
A novel technique highlights patterns in DNA mutation within different cancer types, allowing future genetic changes to be predicted.
Specific genes associated with triple-negative breast cancer risk have been identified by multigene hereditary cancer panel testing.
The largest ever study of its kind has become the first to definitively show an increased risk of blood cancers in relatives of patients.
A gene that’s associated with an autoimmune form of hair loss could be exploited to improve cancer immunotherapy, suggests a new mouse study.
Research has demonstrated that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to BRAF inhibitors.
First-time evidence that individuals at risk of developing AML can be identified, years before diagnosis
Researchers have discovered that it is possible to identify individuals at high risk of developing acute myeloid leukaemia years before diagnosis.
Genetic test could identify prostate cancer patients who are most likely to benefit from immunotherapy
A genetic test could aid the identification of men with prostate cancer who are most likely to benefit from immunotherapy.